deCODE genetics, a subsidiary of the global biotechnology company Amgen, today announced the appointment of Daníel F. Guðbjartsson, Ph.D. as Associate Vice President and Site Head. In this role, Dr. Guðbjartsson will lead site operations for deCODE genetics, further strengthening its human genetics capabilities and supporting the discovery of new therapeutic targets and insights into disease biology.
Dr. Guðbjartsson has played a central role at deCODE genetics since joining in 1998, serving in a series of leadership positions including Head of Statistical Development and, most recently, Chief Scientist. During his time at deCODE, Dr. Guðbjartsson has contributed significantly to the development of the methodologies underlying the company’s large-scale population genetics research and is widely recognized for his commitment to mentorship, talent development and international scientific collaboration.
“I’ve had the opportunity to grow alongside deCODE genetics for many years, and I’m looking forward to taking on this role at a time of rapid advances in experimental technologies and analytical methods, particularly in artificial intelligence,” said Dr. Guðbjartsson. “We will continue to prioritize careful, high-quality science to generate insights from data that can ultimately improve our understanding of disease.”
“Daníel brings deep expertise in the scientific and analytical foundations that define deCODE genetics,” said Howard Chang, M.D., Ph.D., senior vice president, Global Research, and chief scientific officer at Amgen. “deCODE remains central to our global research strategy, and we will continue to build on its strong foundation as a leading hub for genetic research that drives meaningful progress for patients.”